Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
2014 1
2015 1
2016 1
2017 1
2018 1
2019 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

5 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Stage III Borderline Ovarian Surface Epithelial-Stromal Tumor"
Page 1
Ovarian neuroendocrine carcinomas of non-small-cell type associated with surface epithelial adenocarcinomas. A study of five cases and review of the literature.
Eichhorn JH, Lawrence WD, Young RH, Scully RE. Eichhorn JH, et al. Int J Gynecol Pathol. 1996 Oct;15(4):303-14. doi: 10.1097/00004347-199610000-00002. Int J Gynecol Pathol. 1996. PMID: 8886877 Review.
Five primary ovarian carcinomas composed of a high-grade neuroendocrine tumor of non-small-cell type and a surface-epithelial-stromal tumor are reported. ...The tumors were unilateral, 9 to 30 (mean, 16) cm in greatest dimension, and had …
Five primary ovarian carcinomas composed of a high-grade neuroendocrine tumor of non-small-cell type and a surface-e …
Annual report of the committee on gynecologic oncology, the Japan Society of Obstetrics and Gynecology: Annual patients report for 2015 and annual treatment report for 2010.
Nagase S, Ohta T, Takahashi F, Enomoto T; 2017 Committee on Gynecologic Oncology of the Japan Society of Obstetrics and Gynecology. Nagase S, et al. J Obstet Gynaecol Res. 2019 Feb;45(2):289-298. doi: 10.1111/jog.13863. Epub 2018 Nov 13. J Obstet Gynaecol Res. 2019. PMID: 30426591
The 5-year survival rates of the patients with cervical cancer were 92.1%, 74.2%, 52.0%, and 29.8% for stages I, II, III, and IV, respectively. The 5-year survival rates for the patients with endometrial cancer were 94.3%, 88.8%, 74.0% and 26.6% for stages I, …
The 5-year survival rates of the patients with cervical cancer were 92.1%, 74.2%, 52.0%, and 29.8% for stages I, II, III, and …
Annual Report of the Committee on Gynecologic Oncology, Japan Society of Obstetrics and Gynecology: Patient Annual Report for 2014 and Treatment Annual Report for 2009.
Saito T, Takahashi F, Katabuchi H; 2016 Committee on Gynecologic Oncology of the Japan Society of Obstetrics and Gynecology. Saito T, et al. J Obstet Gynaecol Res. 2017 Nov;43(11):1667-1677. doi: 10.1111/jog.13450. Epub 2017 Sep 11. J Obstet Gynaecol Res. 2017. PMID: 28892220
Stage I accounted for 55.6%, stage II for 22.9%, stage III for 10.2%, and stage IV for 11.2% of all patients with cervical cancer. ...Stage I accounted for 43.3%, stage II for 9.1%, stage III for 27.6%, and stage …
Stage I accounted for 55.6%, stage II for 22.9%, stage III for 10.2%, and stage IV for 11.2% of all patie …
Annual Report of the Committee on Gynecologic Oncology, Japan Society of Obstetrics and Gynecology: Patient Annual Report for 2013 and Treatment Annual Report for 2008.
Saito T, Katabuchi H. Saito T, et al. J Obstet Gynaecol Res. 2016 Sep;42(9):1069-79. doi: 10.1111/jog.13043. Epub 2016 Jun 23. J Obstet Gynaecol Res. 2016. PMID: 27338217
Stage I accounted for 56.7%, stage II for 23.4%, stage III for 9.8% and stage IV for 10.2% of all patients with cervical cancer. ...Stage I accounted for 42.2%, stage II for 9.8%, stage III for 28.2% and stage …
Stage I accounted for 56.7%, stage II for 23.4%, stage III for 9.8% and stage IV for 10.2% of all patient …
Annual report of the Committee on Gynecologic Oncology, the Japan Society of Obstetrics and Gynecology.
Yamagami W, Aoki D. Yamagami W, et al. J Obstet Gynaecol Res. 2015 Feb;41(2):167-77. doi: 10.1111/jog.12596. Epub 2014 Nov 5. J Obstet Gynaecol Res. 2015. PMID: 25370711
Stage I accounted for 43.1%, stage II for 9.2%, stage III for 29.7% and stage IV for 7.2% of all patients with ovarian cancer. ...The equivalent rates for patients with endometrial cancer were 96.3%, 92.7%, 80.6% and 35.8%, respectively; …
Stage I accounted for 43.1%, stage II for 9.2%, stage III for 29.7% and stage IV for 7.2% of all patients …